Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator noretreat, TOB, Seel
Search This Board:
Last Post: 8/29/2014 9:47:23 AM - Followers: 115 - Board type: Free - Posts Today: 1



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Statement of Changes in Beneficial Ownership (4) 08/18/2014 07:27:03 PM
IDRA News: Quarterly Report (10-q) 08/12/2014 06:46:41 AM
IDRA News: Idera Pharmaceuticals & Collaborators Publish Promising Preclinical Data Targeting microRNA with Gene Silencing Oligonucleoti... 08/06/2014 08:00:00 AM
IDRA News: Idera Pharmaceuticals to Host Conference Call and Webcast to Report Second Quarter 2014 Financial Results 08/05/2014 08:00:00 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/03/2014 04:44:35 PM
PostSubject
#1337  Sticky Note Idera Pharmaceuticals and Collaborators Publish Promising reclinical Data TOB 08/06/14 11:05:37 AM
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1361   So, we are seeing a reversal? Short THEPK5 08/29/14 09:47:23 AM
#1360   Thanks got email last night to check it ofspring 08/27/14 05:10:50 AM
#1359   Welcome...nice chart...shows very nicely the break of that Citrati 08/27/14 12:04:01 AM
#1358   IDRA hello ofspring 08/26/14 11:05:24 PM
#1357   Nice to see some board activity. Citrati 08/26/14 01:07:32 PM
#1356   Thank you.I appreciate your taking the time to write. stocking4ms 08/26/14 09:31:12 AM
#1355   I'm not a member either, but can see CHM_760 08/26/14 09:06:18 AM
#1354   GM CHM_760, Streetinsider request member log in, can stocking4ms 08/26/14 08:58:25 AM
#1353   Idera Pharmaceuticals (IDRA) Top Small Cap Pick for CHM_760 08/26/14 08:14:48 AM
#1352   Nice Big Bottom forming here. When the run Randolph Duke 08/21/14 06:34:58 PM
#1351   Based on the 1 year old article you Beandog 08/20/14 11:47:31 PM
#1350   Prime takeover candidate! alexwv 08/20/14 05:27:23 PM
#1349   Technicals look really good here! Steady climb alexwv 08/20/14 10:16:24 AM
#1348   Maybe,..I'm at a loss for near term catalysts. Canoepaddler 08/18/14 11:13:46 PM
#1347   Was that the august pop? THEPK5 08/18/14 10:29:44 AM
#1346   $IDRA Cowen Maintains Outperform On Idera Following 2Q14 maytepper 08/13/14 01:51:34 PM
#1345   Seel: thoughts on CC today? Tia Canoepaddler 08/12/14 11:29:29 AM
#1344   To add,....WM data by end of year as Canoepaddler 08/12/14 11:28:56 AM
#1343   WM data presentation at conference in London on Thursday! Canoepaddler 08/12/14 11:18:18 AM
#1342   IDRA....getting some mojo on. Citrati 08/11/14 09:31:00 PM
#1341   Yeah- I've been hearing rumors of a short Randolph Duke 08/09/14 12:32:33 PM
#1340   Looks like a nice double bottom on the Citrati 08/09/14 11:26:57 AM
#1339   Palmer Capital calling for. $3.50 by end of Canoepaddler 08/08/14 09:51:12 PM
#1338   Thank you for posting that! TOB 08/06/14 11:07:55 AM
#1337   Idera Pharmaceuticals and Collaborators Publish Promising reclinical Data TOB 08/06/14 11:05:37 AM
#1336   Nice, thanks for the quick news update. IDRA Citrati 08/06/14 09:28:15 AM
#1335   Circulation Research is probably the most respected basic leakdog 08/06/14 08:36:24 AM
#1334   Yes, it was a good day. Not confirmed Citrati 08/05/14 11:43:57 PM
#1333   Divergence from IBB and major indexes today? Sure Canoepaddler 08/05/14 07:39:55 PM
#1332   So folks better understand why we to talk TOB 08/04/14 10:11:04 PM
#1331   I think we would all hope he is Citrati 08/02/14 04:40:03 PM
#1330   Seems a bit overly optimistic, but I secretly Black sunshine 08/01/14 08:44:54 PM
#1329   Take a look at Palmer's posts on yahoo. Canoepaddler 08/01/14 07:49:04 PM
#1328   How's this looking for next week? Sold Black sunshine 08/01/14 07:19:26 PM
#1327   Just waiting on highest dose group results for Seel 08/01/14 06:42:12 PM
#1326   Almost 1mil shares bought/sold AH @2.44. Any Beandog 08/01/14 05:51:23 PM
#1325   Any thoughts on why the delay with results? Canoepaddler 08/01/14 05:39:43 PM
#1324   Thanks Seel. I just reloaded for the long Canoepaddler 08/01/14 01:19:24 PM
#1323   I'm here. Not a trader - so just Seel 08/01/14 12:17:34 PM
#1320   Where is Seel? Thoughts here? Canoepaddler 07/31/14 07:51:56 PM
#1319   Nah. The techs are all wonky right now. Randolph Duke 07/30/14 11:02:51 AM
#1318   You looking at a reentry point back in THEPK5 07/30/14 09:34:33 AM
#1317   Potential triple bottom...http://stockcharts.com/h-sc/ui?s=IDRA&p=D&b=5&g=0&id=p Citrati 07/28/14 12:38:11 PM
#1316   Yes, the LT up side is significant. Citrati 07/28/14 08:05:10 AM
#1315   I agree. It is hard to tell noretreat 07/28/14 06:44:42 AM
#1314   So far the bb midline is having the Citrati 07/27/14 09:12:39 PM
#1313   Began to rebuild a position here a little noretreat 07/27/14 06:34:07 PM
#1312   Thanks. It is. I've had my eye on MrW 07/24/14 10:29:48 PM
#1311   MrW that is a lot of open interest. Citrati 07/24/14 10:08:27 PM
#1310   HZNP. Crazy swings. A bit of a risk. Randolph Duke 07/23/14 10:17:09 PM
PostSubject